p.4 抽出テキスト

10.2. Patients with multivessel coronary artery disease undergoing primary percutaneous coronary intervention ............ 3770 10.3. Timing of non-infarct-related artery revascularization in acute coronary syndrome ........................................................................... 3771 10.3.1. Patients presenting with ST-elevation myocardial infarction and multivessel coronary artery disease ...................... 3771 10.3.2. Patients presenting with non-ST-elevation acute coronary syndrome and multivessel coronary artery disease . 3771 10.4. Evaluation of non-infarct-related artery stenosis severity (angiography vs. physiology) ....................................................................... 3771 10.5. Hybrid revascularization ................................................................... 3772 11. Myocardial infarction with non-obstructive coronary arteries . 3772 12. Special situations ............................................................................................ 3775 12.1. Type 2 myocardial infarction and acute myocardial injury 3775 12.2. Complications ....................................................................................... 3775 12.2.1. Heart failure ................................................................................... 3775 12.2.2. Mechanical complications ......................................................... 3776 12.2.3. Left ventricular thrombus ......................................................... 3776 12.2.4. Post-acute coronary syndrome pericarditis ..................... 3776 12.2.5. Arrhythmias .................................................................................... 3776 12.2.5.1. Atrial fibrillation .................................................................... 3776 12.2.5.2. Ventricular arrhythmias .................................................... 3777 12.2.6. Bleeding ............................................................................................ 3777 12.2.6.1. Management of bleeding .................................................. 3777 12.3. Comorbid conditions ......................................................................... 3778 12.3.1. Patients at high bleeding risk and with blood disorders (anaemia and thrombocytopaenia) ..................................................... 3778 12.3.2. Chronic kidney disease .............................................................. 3779 12.3.3. Diabetes mellitus .......................................................................... 3779 12.3.4. Older adults with frailty and multimorbidity ................... 3779 12.3.4.1. The older person ................................................................. 3779 12.3.4.2. Frailty and multimorbidity ................................................ 3779 12.3.5. Pregnancy ........................................................................................ 3780 12.3.6. Drug abuse ...................................................................................... 3780 12.3.7. Patients with cancer .................................................................... 3780 12.3.8. Coronavirus disease (COVID-19) ........................................ 3780 13. Long-term treatment ................................................................................... 3781 13.1. Cardiac rehabilitation ......................................................................... 3783 13.1.1. Comprehensive cardiac rehabilitation ................................. 3783 13.1.2. Digital health .................................................................................. 3783 13.1.3. Adherence and persistence ..................................................... 3783 13.2. Lifestyle management ......................................................................... 3783 13.2.1. Tobacco ........................................................................................... 3783 13.2.2. Nutrition and alcohol ................................................................. 3783 13.2.3. Physical activity and exercise .................................................. 3784 13.2.4. Psychological considerations ................................................... 3784 13.2.5. Resumption of activities ............................................................ 3784 13.3. Pharmacological treatment .............................................................. 3784 13.3.1. Antithrombotic therapy ............................................................ 3784 13.3.2. Lipid-lowering therapy ............................................................... 3784 13.3.3. Beta-blockers ................................................................................. 3785 13.3.4. Nitrates and calcium channel blockers ............................... 3786 13.3.5. Renin–angiotensin–aldosterone system inhibitors ......... 3786 13.3.6. Medications for diabetes ........................................................... 3786 13.3.6.1. Sodium–glucose co-transporter 2 inhibitors ........... 3786 13.3.6.2. Glucagon-like peptide-1 receptor agonists .............. 3787 13.3.7. Proton pump inhibitors ............................................................. 3787 13.3.8. Vaccination ...................................................................................... 3787 13.3.9. Anti-inflammatory drugs ........................................................... 3787 13.3.10. Hormone replacement therapy .......................................... 3787 14. Patient perspectives ..................................................................................... 3788 14.1. Patient-centred care ........................................................................... 3788 14.2. Shared decision-making ..................................................................... 3789 14.3. Informed consent ................................................................................ 3789 14.4. Research participation and consent in the acute setting .... 3790 14.5. Patient satisfaction and expectations .......................................... 3790 14.6. Patient-reported outcome measures and patient-reported experience measures ..................................................................................... 3791 14.7. Preparation for discharge ................................................................. 3791 15. Key messages .................................................................................................. 3791 16. Gaps in evidence ............................................................................................ 3793 17. Sex differences ............................................................................................... 3795 18. ‘What to do’ and ‘What not to do’ messages from the Guidelines ................................................................................................................. 3796 19. Quality indicators .......................................................................................... 3801 20. Supplementary data ...................................................................................... 3801 21. Data availability statement ......................................................................... 3801 22. Author information ...................................................................................... 3801 23. Appendix ........................................................................................................... 3801 24. References ........................................................................................................ 3802

Tables of Recommendations

Recommendation Table 1 — Recommendations for clinical and diagnostic tools for patients with suspected acute coronary syndrome .................................................................................................................. 3738 Recommendation Table 2 — Recommendations for non-invasive imaging in the initial assessment of patients with suspected acute coronary syndrome .............................................................................................. 3742 Recommendation Table 3 — Recommendations for the initial management of patients with acute coronary syndrome ................... 3745 Recommendation Table 4 — Recommendations for reperfusion therapy and timing of invasive strategy ....................................................... 3750 Recommendation Table 5 — Recommendations for antiplatelet and anticoagulant therapy in acute coronary syndrome .............................. 3758 Recommendation Table 6 — Recommendations for alternative antithrombotic therapy regimens ........................................... 3759 Recommendation Table 7 — Recommendations for fibrinolytic therapy ....................................................................................................................... 3762 Recommendation Table 8 — Recommendations for cardiac arrest and out-of-hospital cardiac arrest ................................................................. 3763 Recommendation Table 9 — Recommendations for cardiogenic shock .......................................................................................................................... 3764 Recommendation Table 10 — Recommendations for in-hospital management ............................................................................................................ 3766 Recommendation Table 11 — Recommendations for technical aspects of invasive strategies ............................................................................ 3769 Recommendation Table 12 — Recommendations for management of patients with multivessel disease .............................................................. 3772 Recommendation Table 13 — Recommendations for myocardial infarction with non-obstructive coronary arteries ................................. 3775 Recommendation Table 14 — Recommendations for acute coronary syndrome complications ................................................................ 3777 Recommendation Table 15 — Recommendations for acute coronary syndrome comorbid conditions ................................................. 3781

ESC Guidelines                                                                                                                                                                                          3723

Downloaded from academic.oup.com/eurheartj/article/44/38/3720/7243210 by guest on 07 October 2026